BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Amsterdam
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200930T090000
DTEND;TZID=America/New_York:20200930T121500
DTSTAMP:20260403T194301
CREATED:20200908T153930Z
LAST-MODIFIED:20200924T134830Z
UID:4317-1601456400-1601468100@carb-x.org
SUMMARY:Longitude Prize Sprint Workshop: How to Attract Investment
DESCRIPTION:Recent CARB-X graduate\, Specific Diagnostics\, will be participating in this workshop. \nThis workshop will be a forum for start-up and SMEs developing diagnostic tests to: \n\nHear from successful entrepreneurs who have built diagnostic companies\, what do they think were their key factors for success?\nHear from venture capital investors about what they expect and need before making investments.\nMeet in small break-out sessions in which you will interact directly with other medtech startups who have built or are in midst of building their enterprises and share insights.\nParticipate in panel discussion where you can ask both medtech leaders and venture capital fund managers about the intricacies and nuances of dilutive fund raise.\n\nNote: this webinar is the second in the Longitude Prize Sprint series. \nMore details can be found on the Longitude Prize website here. Registration is limited\, if you have trouble registering please send an email to longitude.prize@nesta.org.uk \nTo view the agenda\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/longitude-prize-sprint-workshop-how-to-attract-investment/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201002
DTEND;VALUE=DATE:20201003
DTSTAMP:20260403T194301
CREATED:20200824T155054Z
LAST-MODIFIED:20200924T135933Z
UID:4304-1601596800-1601683199@carb-x.org
SUMMARY:Boston Area Antimicrobial Resistance Network (BAARN) Meeting
DESCRIPTION:CARB-X speakers include Su Chiang\, Alliance Manager. \nThe 7th BAARN meeting will bring together the leading voices in academia and industry to addresss a defining global health crisis of our age: antibiotic resistant infection. \nThis year will be BAARN’s inaugural virtual meeting. We are using online platforms to present an amazing lineup of researchers and innovators\, accessible to anyone with an internet connection. The event will stream on YOUTUBE LIVE. Zoom and YouTube Live links will be sent upon registration. \nThis event is co-coordinated by the Harvard Microbial Sciences Initiative and the Harvard Infectious Disease Institute. \nTo learn more\, click here. \nTo register\, click here.
URL:https://carb-x.org/event/boston-area-antimicrobial-resistance-network-baarn-meeting/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260403T194301
CREATED:20200817T133102Z
LAST-MODIFIED:20200924T145717Z
UID:4270-1602115200-1602287999@carb-x.org
SUMMARY:World Antimicrobial Resistance Congress 2020
DESCRIPTION:Erin Duffy\, CARB-X Chief of R&D\, is the chairperson of the event as well as a participant in a number of panels.  Other participants from CARB-X include Kevin Outterson (Executive Director)\, Richard Alm (Therapeutic R&D Alliance Director)\, Ed Buurman (Prevention R&D Alliance Director) and Betsy Wonderly Trainor (Diagnostic R&D Alliance Director).\n\nThe 6th annual World Antimicrobial Resistance Congress will be held virtually October 8-9\, 2020. It will showcase more than 250 presentations\, including speakers from CARB-X funded companies\, Forge and Entasis. \nAnti-microbial resistance continues to grow as a critical healthcare crisis globally. The number of deaths attributed to this epidemic is exponentially increasing\, and most measures and policies to combat AMR are deemed insufficient.Since 2015\, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space to meet\, brainstorm ideas and formulate initiatives that can effectively tackle this pressing issue. \nIndustry leaders\, innovative technology and solution providers\, public authorities\, international organizations\, infectious disease clinicians\, pharmacists and microbiologists are some of the 1\,000+ attendees from over 50 countries who will gather virtually this October 2020 at the World Anti-Microbial Resistance Congress. \nIf you work in these key areas of AMR\, then you must attend the World Anti-Microbial Resistance Congress 2020! \n\nClick here for more information.\nClick here to register.
URL:https://carb-x.org/event/world-antimicrobial-resistance-congress-2020/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201015T090000
DTEND;TZID=America/New_York:20201015T100000
DTSTAMP:20260403T194301
CREATED:20200916T174706Z
LAST-MODIFIED:20200916T174706Z
UID:4345-1602752400-1602756000@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Prevention is stronger than a cure
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nPreventing drug resistant infections reduces the use of antibiotics and improves patient outcomes. Infection control practices\, from simple hand-washing to global vaccination\, and the use of effective infection prevention measures are key tools to combat COVID-19 and AMR. How has the COVID-19 pandemic informed our infection prevention efforts for healthcare systems and individuals around the world? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-prevention-is-stronger-than-a-cure/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201022
DTSTAMP:20260403T194301
CREATED:20200924T150127Z
LAST-MODIFIED:20200924T150127Z
UID:4402-1603065600-1603324799@carb-x.org
SUMMARY:5th Microbiome Movement - Drug Development Summit 2020
DESCRIPTION:The study of the human microbiome remains one of the most exciting frontiers in modern medicine that if targeted correctly\, has the potential to benefit millions of patients suffering from numerous diseases. However\, the potential for effective medicines powered by the microbiome is matched by the unique challenges in developing them. \nThe Microbiome Movement – Drug Development Summit returns as the “must attend meeting for the translational microbiome community” to help cutting-edge pharmaceutical and academic researchers pursue the causal role of the human microbiome in disease to help deliver a new generation of targeted therapeutics\, biomarker and diagnostics that demonstrate consistent clinical outcomes and predictabe MoAs. \nSo whether you’re part of a microbiome-focused biotech\, a pharmaceutical organization assessing this exciting field\, or an academic researcher with breakthrough findings\, join the Microbiome Movement as we explore the global advances in translational microbiome research\, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the ‘second genome’. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/5th-microbiome-movement-drug-development-summit-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201019T040500
DTEND;TZID=America/New_York:20201019T040500
DTSTAMP:20260403T194301
CREATED:20200916T173318Z
LAST-MODIFIED:20200924T150708Z
UID:4341-1603080300-1603080300@carb-x.org
SUMMARY:World Vaccine Congress Europe: Changing the paradigm and finding a sustainable way to tackle AMR - The need for alternatives to antibiotics
DESCRIPTION:CARB-X speakers include Ed Buurman\, Alliance Director. \nTopics covered include: \n\nHow big is the problem economically speaking?\nShould we phase out broad-spectrum antibiotics?\nProgrammatic & technical challenges\nWhat can vaccines bring?\n\nClick here to view the agenda.\nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/world-vaccine-congress-europe-changing-the-paradigm-and-finding-a-sustainable-way-to-tackle-amr-the-need-for-alternatives-to-antibiotics/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201021
DTEND;VALUE=DATE:20201026
DTSTAMP:20260403T194301
CREATED:20200908T155407Z
LAST-MODIFIED:20200908T160006Z
UID:4321-1603238400-1603670399@carb-x.org
SUMMARY:IDWeek 2020
DESCRIPTION:To learn more\, click here.\nTo view the program\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/idweek-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201030
DTSTAMP:20260403T194301
CREATED:20200908T155855Z
LAST-MODIFIED:20200908T161523Z
UID:4323-1603670400-1604015999@carb-x.org
SUMMARY:38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020)
DESCRIPTION:The 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020) will be held on 26-29 October 2020 as a fully virtual meeting. \nThe organization of the meeting is a joint effort of ESPID members from the Netherlands. The ESPID forms the basis for investigators interested in infectious diseases in children and infection prevention in childhood. The main intent of the meeting is to bring together the most prominent researchers in and relevant to the field of paediatric infectious diseases and immunology. The meeting will provide an opportunity to exchange knowledge and generate new ideas in a relaxed\, smart albeit casual atmosphere. \nTo learn more\, click here.\nTo view the program\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/38th-annual-meeting-of-the-european-society-for-paediatric-infectious-diseases-espid-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201028
DTSTAMP:20260403T194301
CREATED:20200908T160156Z
LAST-MODIFIED:20201020T143659Z
UID:4326-1603756800-1603843199@carb-x.org
SUMMARY:BARDA Industry Day
DESCRIPTION:BARDA Industry Day is the annual meeting held to increase potential partner’s awareness of U.S. Government medical countermeasure priorities\, interact with BARDA and ASPR staff\, and network with public and private sector colleagues working in the Health Security space. This year\,  BARDA Industry Day 2020 will be virtual and will feature one day of exciting speakers\, breakout sessions\, and valuable networking opportunities!  The primary mission of BARDA’s industry day is to advance innovation and development of medical countermeasures\, bring together potential collaborators from across organizations\, share our accomplishments among our stakeholders\, and provide BARDA’s vision for the upcoming year’s priorities. \nBARDA\, through the CARB-X and Drive programs\, is supporting a networks of wrap-around-service-oriented accelerators that can be leveraged to prepare partners for donor funding. The hope is to fill and maintain a pipeline of partners ready and able to apply for advanced research support while bolstering the market of life-saving countermeasures. DRIVE and CARB-X will organize a panel of BARDA supported accelerators who will describe how “wrap-around services” have actually lead to better products (fitting the BID theme of ‘responding together’. At the end of the panel\, we will moderate a Q&A with audience members. Promotional material from other accelerators will be made available digitally for audience members. \nTo learn more\, click here.
URL:https://carb-x.org/event/barda-industry-day-2/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201028T040000
DTEND;TZID=America/New_York:20201028T053000
DTSTAMP:20260403T194301
CREATED:20201026T142510Z
LAST-MODIFIED:20201026T142557Z
UID:4512-1603857600-1603863000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Developing antibiotics for children – medical need and regulatory challenges
DESCRIPTION:Speakers: \nPhoebe Williams\, Sydney Children’s Hospital and University of Sydney (Australia)\, will discuss: \n\nStatus quo – what antibiotics do we have (left) for children and babies\nWhere is the biggest medical need?\nChallenges of clinical trials in children – the clinicians perspective\nWhat impact will new drugs have in day-to-day practice and how does this depend on the setting (e.g. LMICs vs. high-income; community vs. hospital)?\n\nIrja Lutsar\, University of Tartu (Estonia)\, will discuss: \n\nClinical development of antibiotics for children; incl. new formulations of existing antibiotics including general regulatory requirements\nBrief overview of the type of data required for a new antibiotic for paediatric use; i.e. PK and other data\nChallenges of clinical trials in children and babies – the drug developers/regulatory perspective\n\nModerator: Sally Ellis (GARDP)  \nThe presentations will be followed by a Q&A session. \nTo learn more\, click here. 
URL:https://carb-x.org/event/live-webinar-gardp-revive-saving-childrens-lives-treating-neonatal-sepsis/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20201029T160000
DTEND;TZID=Europe/Paris:20201029T180000
DTSTAMP:20260403T194301
CREATED:20201013T195519Z
LAST-MODIFIED:20201013T195519Z
UID:4453-1603987200-1603994400@carb-x.org
SUMMARY:Interdisciplinary Course on Antibiotics and Resistance (ICARe) Webinar:
DESCRIPTION:Panelists include Erin Duffy\, CARB-X Chief of R&D \nPlease join us for a special ICARe webinar in light of the course’s 5th anniversary.  This two-hour event\, hosted by ICARe director Patrice Courvalin (Institut Pasteur\, France)\, will feature four 20-minute presentations from leading experts in antimicrobial resistance and antibiotic discovery research. Presentations will follow with a 30-minute panel discussion. \nThe webinar schedule is as follows: \n\n4:00: Patrice Courvalin (Institut Pasteur\, France) – Introduction\n4:05: Helen Boucher (Tufts Medical Center\, USA) – “Syndemics of AMR and COVID”\n4:25: Gerry Wright (McMaster University\, Canada) – “What’s new in antibiotic resistance?”\n4:45: Erin Duffy (CARB-X\, USA) – “Innovation in antibiotic discovery”\n5:05: John Rex (F2G\, UK)- “Prospects and remaining challenges in antibiotic development”\n5:25: Panel Discussion\n5:55: Patrice Courvalin (Institut Pasteur\, France) – Closing Remarks\n\nTo learn more\, click here.\nTo register\, click here.   \nAfter registering\, you will receive a confirmation email containing information about joining the webinar. Please note that the webinar start time is in Paris Time.​
URL:https://carb-x.org/event/interdisciplinary-course-on-antibiotics-and-resistance-icare-webinar/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201105T090000
DTEND;TZID=America/New_York:20201105T100000
DTSTAMP:20260403T194301
CREATED:20200916T174813Z
LAST-MODIFIED:20201013T200205Z
UID:4346-1604566800-1604570400@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Aiming in the dark: what happens when disease spreads without diagnosis
DESCRIPTION:Panelists include Erin Duffy\, CARB-X Chief of R&D \nAMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nThe pandemic has demonstrated the critical role of diagnostic testing to steer our public health response. It has been shown that diagnostic testing for bacterial and fungal infections results in improved use of antibiotics and antibiotic stewardship. But whereas testing for COVID-19 has benefited from innovation and rapid uptake\, testing for drug resistant infections remains underutilized. How can we improve the effective use of diagnostics\, globally\, for the diagnosis of bacterial and viral infections? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-aiming-in-the-dark-what-happens-when-disease-spreads-without-diagnosis/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201117
DTSTAMP:20260403T194301
CREATED:20201013T201730Z
LAST-MODIFIED:20201013T201930Z
UID:4460-1605484800-1605571199@carb-x.org
SUMMARY:FDA Public Workshop: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs
DESCRIPTION:The Food and Drug Administration (FDA\, the Agency\, or we) is hosting a virtual public meeting entitled “Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs.” The purpose of the meeting is to obtain early input from the public on a potential revised approach for considering the human medical importance of antimicrobial new animal drugs when assessing and managing the antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. The Agency is seeking public input on a potential revised process for ranking antimicrobials according to their relative importance in human medicine\, on the potential criteria for their ranking\, and on the resulting ranked list of antimicrobial drugs. A concept paper describing this potential revised process will be made available for discussion at the public meeting. \nClick here to learn more.\nClick here for the concept paper posted in advance of the meeting.
URL:https://carb-x.org/event/fda-public-workshop-potential-approach-for-ranking-of-antimicrobial-drugs-according-to-their-importance-in-human-medicine-a-risk-management-tool-for-antimicrobial-new-animal-drugs/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201117T100000
DTEND;TZID=America/New_York:20201117T110000
DTSTAMP:20260403T194301
CREATED:20201104T141806Z
LAST-MODIFIED:20201110T151145Z
UID:4546-1605607200-1605610800@carb-x.org
SUMMARY:CARB-X WEBINAR: Tackling Drug-resistant Bacteria: Exciting Science in the CARB-X Portfolio - Vedanta\, Eligo\, Peptilogics
DESCRIPTION:Join us Tuesday\, November 17\, at 10 AM – 11 AM ET for an update on CARB-X\, and an insider’s look at 3 innovative programs supported by CARB-X \nCARB-X is hosting this special webinar to showcase some of the exciting science in the CARB-X portfolio and the progress CARB-X is making supporting the development of innovative therapeutics\, preventatives and rapid diagnostics to address antibiotic-resistant bacteria. \nThe webinar will be moderated by Kevin Outterson\, Executive Director of CARB-X\, and will feature \n\nErin Duffy\, CARB-X R&D Chief\, on portfolio priorities and progress\nXavier Duportet\, Co-Founder and CEO of Eligo Bioscience\, on Eligo’s innovative CRISPR-based therapeutics derived from bacteriophages to prevent and treat antibiotic-resistant infections in transplant patients\nJonathan Steckbeck\, Founder and CEO of Peptilogics\, on the development of their first-in-class antibiotic peptide for the treatment of prosthetic joint infections which recently was granted Orphan Drug Designation by the US Food and Drug Administration\nBernat Olle\, Co-Founder and CEO of Vedanta Biosciences\, on Vedanta’s microbiome program\, including VE707\, an oral therapeutic designed to restore a patient’s healthy microbiota to that it can fight multidrug-resistant bacteria\, and VE303\, which has recently become the first CARB-X-funded therapeutic to go on to secure BARDA support for late-stage development\, and is also the first-ever BARDA award for research and development of a live bio-therapeutic product.\n\nA virtual Q&A will also be held. \nCLICK HERE TO REGISTER TODAY:\nOnce you register\, you will receive a confirmation and will be able to download an invitation to your calendar.
URL:https://carb-x.org/event/carb-x-webinar-tackling-drug-resistant-bacteria-exciting-science-in-the-carb-x-portfolio/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201117T110000
DTEND;TZID=America/New_York:20201117T123000
DTSTAMP:20260403T194301
CREATED:20201026T143033Z
LAST-MODIFIED:20201026T143155Z
UID:4511-1605610800-1605616200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
DESCRIPTION:Speakers: \n\nJames J. Collins\, Termeer Professor of Medical Engineering & Science Professor\, Broad Institute of MIT and Harvard (USA)\nCesar de la Fuente\, Presidential Assistant Professor\, University of Pennsylvania (USA)\nHenriette Willems\, Senior Research Associate\, The ALBORADA Drug Discovery Institute\, University of Cambridge\, (UK)\nFredrik Svensson\, Senior Research Associate\, UCL Drug Discovery Institute\, London\, (UK)\n\nModerator:  \n\nLaura Piddock\, Director of Scientific Affairs\, GARDP\n\nIn this webinar\, the speakers will give an overview of their work on the discovery of antibiotics through the use of artificial intelligence. The session will include the following presentations: \n\nDeep learning approaches to antibiotic discovery – James J. Collins\nAntibiotic discovery by means of computers – Cesar de la Fuente\nComputational Chemistry on a Budget – Henriette Willems & Fredrik Svensson\n\nTo learn more\, click here. 
URL:https://carb-x.org/event/live-webinar-gardp-revive-discovery-of-new-antibacterials-using-artificial-intelligence-computational-chemoinformatics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201125
DTSTAMP:20260403T194301
CREATED:20201110T184941Z
LAST-MODIFIED:20201110T184941Z
UID:4564-1605657600-1606262399@carb-x.org
SUMMARY:World Antimicrobial Awareness Week 2020
DESCRIPTION:The theme for World Antimicrobial Awareness Week 2020 for the human health sector is “United to preserve antimicrobials.” \nEvery year\, World Antimicrobial Awareness Week aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public\, health workers and policy makers to stop the further emergence and spread of drug-resistant infections. \nWAAW has expanded its scope to address not just antibiotics\, but all antimicrobials\, including antiviral\, antifungal and antiparasitic medicines. This exciting decision came on the strong recommendation of the antimicrobial resistance (AMR) community. In the midst of a global pandemic\, stakeholders came together virtually to discuss the challenges and opportunities for the WAAW campaign and awareness of Antimicrobial Resistance (AMR) more generally. The overarching message was that all sectors needed to unite to change behaviours and that the campaign needed to broaden its scope from antibiotics\, to include all antimicrobials. \nFor the first time ever\, we are also celebrating WAAW at a time when traditional methods of campaigning are not possible. We are challenged by new rules of social distancing\, limitations on public gatherings\, and physical isolation. As with the global virtual consultation in May 2020\, however\, the AMR community has shown its commitment\, resilience and eagerness to celebrate\, unite\, and build awareness around an issue that is becoming one of the most significant challenges to our global health and development objectives. Over the 7 days of WAAW 2020\, events will be held virtually in all regions of the world\, by governments\, academics\, students\, health care workers\, NGOs and all those interested and passionate about combating AMR. \nTo learn more\, click here.
URL:https://carb-x.org/event/world-antimicrobial-awareness-week-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20201118T093000
DTEND;TZID=Europe/Amsterdam:20201118T174500
DTSTAMP:20260403T194301
CREATED:20201110T160522Z
LAST-MODIFIED:20201112T205559Z
UID:4561-1605691800-1605721500@carb-x.org
SUMMARY:Emerging Antimicrobials and Diagnostics in AMR 2020
DESCRIPTION:CARB-X participants include Nadia Cohen\, Alliance Manager\, who will present during the Accelerating AMR R&D section of the program at 10:40 EST\, and Betsy Wonderly Trainor\, Alliance Director\, who will present at 10:20 EST. \nLearn about the latest AMR technologies in a series of interactive key note lectures by international Captains of Industry and Leading Scientists. \nInteractive\, one day online event providing an international podium for emerging preventives\, antimicrobial strategies\, microbial diagnostics and related (platform) technologies: key note lectures\, technology and product updates\, frontline stories and concluding Q&A session. \nThe event is composed of 3 building sections:\nI: Setting the scene of AMR R&D (09:30 – 12:30 AM)\nII: Technology and Product Updates in AMR (01:00 – 03:50 PM)\nIII: Accelerating AMR R&D (04:00 – 05:45 PM). \nDate: 18 November\, 2020; 09:30 AM – 05:45 PM CET\nThe event is delivered digitally in collaboration with KIT Royal Tropical Institute in Amsterdam and marks the beginning of the World Antimicrobials Awareness Week. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/emerging-antimicrobials-and-diagnostics-in-amr-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201118T100000
DTEND;TZID=America/New_York:20201118T110000
DTSTAMP:20260403T194301
CREATED:20201116T145029Z
LAST-MODIFIED:20201116T145029Z
UID:4582-1605693600-1605697200@carb-x.org
SUMMARY:Wellcome Trust Webinar: The Global Response to drug-resistant infections - momentum\, success and critical gaps
DESCRIPTION:Over the last year\, Wellcome has mapped the global response to AMR to identify progress made since the UN High-Level Meeting on AMR held in 2016.  The analysis captures the views of over 150 experts and reviewed more than 250 documents and aims to bring all this together in a critical path for what the global response to AMR could look like now\, and beyond 2030. \nRecognizing the impact of Covid-19\, the work was expanded to understand if the pandemic has changed how we position efforts to address AMR. The work has been critical in informing Wellcome’s strategic approach toward ending drug-resistant infections and we hope it will benefit other stakeholders by helping to inform where urgent focus is needed. \nJoin us for the launch of this important piece of work\, reflect on what it means to you and your work and hear the reactions of others. \nYou can download the full report here.  \nTo learn more\, click here.\nTo view the agenda\, click here.\nTo register\, click here. \n  \nThe meeting will start at 3PM GMT / 10AM EST
URL:https://carb-x.org/event/wellcome-trust-webinar-the-global-response-to-drug-resistant-infections-momentum-success-and-critical-gaps/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201119T090000
DTEND;TZID=America/New_York:20201119T100000
DTSTAMP:20260403T194301
CREATED:20200924T151233Z
LAST-MODIFIED:20200924T151233Z
UID:4408-1605776400-1605780000@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments\, researchers\, clinicians\, industry and patients
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nGovernments\, researchers\, and industry partners around the world have mobilized to develop diagnostics\, therapeutics\, and vaccines for COVID-19. The development of new recommendations and practices continue to be deployed to slow the spread of COVID-19. The burden of drug-resistant infections could surpass COVID-19. Drugs like antibiotics are a vital tool for modern medicine\, used to prevent and treat infections. As drug-resistant infections are becoming more common\, modern medicine as we know it is at risk and much like COVID-19\, it has the potential to overwhelm our healthcare structure. What changes are needed to reshape strategies for combatting antimicrobial resistance globally? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-responding-to-difficult-to-treat-infections-role-and-responsibilities-of-governments-researchers-clinicians-industry-and-patients-2/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201120T043000
DTEND;TZID=America/New_York:20201120T060000
DTSTAMP:20260403T194301
CREATED:20201026T142835Z
LAST-MODIFIED:20201026T142835Z
UID:4510-1605846600-1605852000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Saving childrens’ lives – treating neonatal sepsis
DESCRIPTION:Speakers: \n\nProf Hanan Balkhy\, Assistant Director-General for Antimicrobial resistance\, WHO\nDr Manica Balasegaram\, Executive Director\, GARDP – Dr Dhanya Dharmapalan\, paediatrician and member of the Pediatric Infectious Disease Society (PIDS)\, Mumbai\nDr Borna Nyaoke\, Senior Clinical Project Manager\, DNDi/GARDP Kenya\n\nModerator:  \n\nDr Peter Beyer\, Senior Advisor\, AMR Division\, WHO The presentations will be followed by a Q&A session.\n\nThe webinar\, organized in collaboration with WHO\, is being held on the occasion of Universal Children’s Day and during World Antimicrobial Awareness Week. It will focus on the challenges in treating newborns suffering from drug-resistant sepsis and finding new treatment options. \nTo learn more\, click here. 
URL:https://carb-x.org/event/live-webinar-gardp-revive-saving-childrens-lives-treating-neonatal-sepsis-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201130
DTEND;VALUE=DATE:20201204
DTSTAMP:20260403T194301
CREATED:20200924T152007Z
LAST-MODIFIED:20200924T152007Z
UID:4410-1606694400-1607039999@carb-x.org
SUMMARY:World Vaccine and Immunotherapy Congress West Coast 2020
DESCRIPTION:In December 2019 SARS-CoV-2 the cause of COVID-19\, was responsible for thousands of deaths in Wuhan\, China. By March 11\, 2020\, WHO declared COVID-19 as a worldwide pandemic.The single most effective way to tackle this pandemic is a working vaccine\, which is why Vaccine Congress West Coast is bringing together experts who have been working tirelessly to make this happen\, in a safe\, virtual environment. This is the most important meeting you will be part of. Now more than ever\, we need everyone’s contribution to solve this global problem. \nCome together and join us VIRTUALLY to identify the urgent priorities for research. To mobilize\, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak\, and commit with our experts how you can learn mechanisms for continuing scientific interactions and collaborations\, now and beyond the congress. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/world-vaccine-and-immunotherapy-congress-west-coast-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201203
DTSTAMP:20260403T194301
CREATED:20201202T230539Z
LAST-MODIFIED:20201202T230539Z
UID:4663-1606867200-1606953599@carb-x.org
SUMMARY:Global AMR Hub Virtual Conference
DESCRIPTION:Translating AMR R&D mapping into policy and action.\nThe Global AMR R&D Hub\, through its Dynamic Dashboard\, is the global knowledge centre for AMR R&D. The Dynamic Dashboard captures and presents: AMR R&D investments from across the globe and One Health sectors; what new antibacterials are in the pipeline; and what is being done to overcome the challenges hindering the development of\, and access to and stewardship of\, priority antibacterials. The important next step for the Global AMR R&D Hub is to take the repository of information\, that is the Dynamic Dashboard\, and translate this into policy and action. \nThis virtual conference is the start of this next important step for the Global AMR R&D Hub. The virtual conference begins discussions to inform how the Global AMR R&D Hub\, using its Dynamic Dashboard\, can support the AMR R&D needs in the different regions and countries\, by highlighting gaps that need to be filled and helping to identify collaboration or partnership opportunities. The three sessions of the conference focus on three different areas to do this: \nCARB-X participants include Kevin Outterson\, Executive Director\, and Erin Duffy\, Chief of Research & Development. \nClick here to learn more.
URL:https://carb-x.org/event/global-amr-hub-virtual-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201205
DTSTAMP:20260403T194301
CREATED:20201202T232133Z
LAST-MODIFIED:20201202T232133Z
UID:4664-1606867200-1607126399@carb-x.org
SUMMARY:Infectious Diseases Virtual Partnering
DESCRIPTION:Infectious diseases have always impacted human history\, but in the past 50 years we have managed to control or eliminate some infectious diseases through improved hygiene\, vaccination\, antimicrobials\, advances in medicine and public health policies. However\, the current pandemic is a reminder that we need to continue to pursue our efforts to control these pathogens\, especially with intercontinental travel and increased mobility of people and animals. \nTo manage infectious diseases\, we use tools such as vaccines\, antibiotics\, antivirals\, diagnostic tools and biomarkers. But today there are many infectious diseases for which we do not have satisfactory preventive tools or treatment options\, such as SARS-CoV-2\, Zika virus\, Ebola virus\, multidrug resistant bacteria\, HIV\, Malaria. To develop these future tools\, collaboration is essential\, either for sourcing assets in the vaccine\, antiviral or antibiotic space\, or for finding research tools to help in screening\, in-vivo modelling\, clinical trials and diagnostics and biomarkers. \nIt is in this context that we are organising the Infectious Diseases Virtual Partnering event\, focusing on diseases caused by organisms such as bacteria\, viruses\, fungi\, or parasites. With current travel restrictions\, this virtual event will help you to find the right business partner to pursue your objectives.  This event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/infectious-diseases-virtual-partnering/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201203T030000
DTEND;TZID=America/New_York:20201203T043000
DTSTAMP:20260403T194301
CREATED:20201112T205113Z
LAST-MODIFIED:20201112T205113Z
UID:4572-1606964400-1606969800@carb-x.org
SUMMARY:Evidence to Action Webinar: Advancing the Antimicrobial Resistance agenda during a pandemic
DESCRIPTION:How can efforts to implement Antimicrobial Resistance National Action Plans still progress despite the COVID-19 pandemic? \nThere is no doubt COVID-19 currently represents the most obvious and urgent issue for global health security and the world is rightfully focused on tackling this pandemic. However\, the challenges posed by COVID-19 are only a foretaste of what antimicrobial resistance (AMR) can mean to the world without appropriate interventions. AMR\, the silent pandemic\, can impact many of the global health achievements of past decades and jeopardize efforts to deliver on many of the Sustainable Development Goals. \nThis webinar provides an opportunity to gain insights into current efforts to continuously move forward the agenda of combatting AMR amidst the COVID-19 pandemic. Key experts and opinion leaders will share their strategic reflections and insights focusing on what evidence and data are currently available and how best to leverage them into action to tackle AMR\, especially in low- and middle-income countries. \nThis event is co-hosted by the International Vaccine Institute (IVI)\, the International Centre for Antimicrobial Resistance Solutions (ICARS) and the Embassy of Denmark in Korea. Speakers from IVI\, ICARS\, WHO and the UK will lead the panel discussion. Please join the conversation and ask questions to our panel. \nTo learn more\, click here. \nTo register\, click here.\nPlease note that registration is required\, and a link to webinar will be shared in advance to registered attendees \nDecember 3\, 2020\n9:00-10:30 AM (CET); 5:00-6:30 PM (KST); 3:00-4:30 AM (EST)
URL:https://carb-x.org/event/evidence-to-action-webinar-advancing-the-antimicrobial-resistance-agenda-during-a-pandemic/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201211
DTSTAMP:20260403T194301
CREATED:20201029T160029Z
LAST-MODIFIED:20201128T210915Z
UID:4523-1607299200-1607644799@carb-x.org
SUMMARY:Milken Institute Future of Health Summit
DESCRIPTION:The Milken Institute Future of Health Summit convenes the best minds in the world to confront the most significant health challenges by matching human\, financial\, scientific\, and educational resources with innovative and impactful ideas. The Summit will focus on the converging crises of public health\, economic insecurity\, and social injustice. COVID-19 has exposed weaknesses across our health systems\, particularly in the treatment of our most vulnerable communities\, where access to affordable and quality health care has never been more vital. \nParticipants include Kevin Outterson\, Executive Director of CARB-X\, who will be moderating a session entitled “Are Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives” on Tuesday\, December 8th from 12:00pm – 1:00pm EST. \nAre Resistant Infections the Next Pandemic? New Antibiotics Need New Incentives: Antibiotic treatment in COVID-19 patients is driving antimicrobial resistance (AMR) as secondary infections emerge. While large pharmaceutical companies have retreated from antibiotic development\, smaller enterprises have compensated with innovative therapies to ensure an arsenal of anti-infective drugs. But numerous recent bankruptcies show that times are tough even for companies with newly approved antibiotics. Several large pharmaceutical companies recently joined in launching the billion-dollar Antimicrobial Action Fund for antibiotic development. This welcome investment buys time to right the market\, but it is clear that a pull incentive is needed to drive the market. What are the lessons to learn from the UK NHS NICE subscription-model pilot? Is a pull incentive enough to attract private investment to antimicrobials? How can we develop a sustainable market for antibiotics so that drug-resistant infections do not become the next pandemic? \nSpeakers Include: \n\nMichael Boyle\nPresident and CEO\, Cystic Fibrosis Foundation\nNick Crabb\nProgramme Director\, Scientific Affairs\, National Institute for Health and Care Excellence (NICE)\nSally Davies\nUK Special Envoy on Antimicrobial Resistance\, UK Government\nOdysseas Kostas\nPartner and Senior Managing Director\, Sarissa Capital\n\nTo learn more\, click here.\nTo view the program\, click here.
URL:https://carb-x.org/event/milken-institute-future-of-health-summit/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201212
DTSTAMP:20260403T194301
CREATED:20201202T232424Z
LAST-MODIFIED:20201202T232424Z
UID:4665-1607299200-1607731199@carb-x.org
SUMMARY:2020 ASM Conference on Next-Generation Sequencing
DESCRIPTION:Join us at the virtual 2020 ASM Conference on Next-Generation Sequencing\, taking place Dec. 7-11\, 2020\, and get comprehensive guidance with up-to-date examples in the use of NGS technology for applied results in the traceability and clustering of microbial pathogens associated with food safety\, clinical infection\, environmental contamination and other potential sources of disease outbreaks. You’ll walk away with access to the available resources and direction you need relating to bioinformatics and epidemiology. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/2020-asm-conference-on-next-generation-sequencing/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260403T194301
CREATED:20201112T203844Z
LAST-MODIFIED:20220803T215834Z
UID:4573-1607385600-1607644799@carb-x.org
SUMMARY:BLUE KNIGHT™ Symposium
DESCRIPTION:CARB-X participants include Erin Duffy\, Chief of R&D. \nJohnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA)\, a component of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services\, to form Blue Knight. This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. Find out more about BARDA and its mission at www.PHE.gov/BARDA. \nIn seeking to combat emerging infectious diseases and other 21st century health threats\, the path to better prepared\, protected\, and healthy individuals\, families\, and communities could rely on unlocking the collective power of the global community. BLUE KNIGHT™ seeks to answer this call. \nOn December 8-10\, Johnson & Johnson Innovation – JLABS and BARDA will virtually convene the emerging Blue Knight community of thought leaders\, innovators and entrepreneurs for a three-day symposium\, including interactive sessions focused on key areas of interest in infectious disease\, public health\, and company acceleration. Sessions will explore high priority areas of interest for scientific and technological innovation aimed for improving our preparedness and response to emerging health security threats. \nTo learn more\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/blue-knight-symposium/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210105
DTEND;VALUE=DATE:20210106
DTSTAMP:20260403T194301
CREATED:20201202T233712Z
LAST-MODIFIED:20201202T233753Z
UID:4672-1609804800-1609891199@carb-x.org
SUMMARY:National Academy of Science
DESCRIPTION:The National Academy of Sciences (NAS) is a private\, nonprofit organization of the country’s leading researchers. The NAS recognizes and promotes outstanding science through election to membership; publication in its journal\, PNAS; and its awards\, programs\, and special activities. Through the National Academies of Sciences\, Engineering\, and Medicine\, the NAS provides objective\, science-based advice on critical issues affecting the nation. \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more.
URL:https://carb-x.org/event/national-academy-of-science/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210114T110000
DTEND;TZID=America/New_York:20210114T123000
DTSTAMP:20260403T194301
CREATED:20201215T155536Z
LAST-MODIFIED:20201215T155536Z
UID:4822-1610622000-1610627400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Manipulating the host response to treat infections
DESCRIPTION:Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock):  \n\nHost defence peptides (HDP; often termed antimicrobial peptides) stimulate protective immunity while suppressing potentially harmful inflammation. Both of these activities can assist in anti-infective therapy.\nHDPs work as immune modulators in animal models against ESKAPE pathogen\, MDR TB\, fungal\, malaria and viral infections\, as well as sterile inflammation. They are likely to be employed in adjunctive therapy in combination with antibiotics.\nHDPs often have additional value-added activities including action against bacterial biofilms in animal models. This allows them to be utilized to address situations where antibiotics commonly fail.\nAlternative host-directed therapies can be defined for recalcitrant infections using stem cell mutagenesis and systems biology approaches.\n\nRegulation and reprogramming of the innate immune system as alternative to antibiotics (Henk P. Haagsman):  \n\nHost defence peptides (HDP) are immunomodulatory antimicrobials. – Cathelicidin-derived peptides may serve as paradigms to develop anti-inflammatory anti-infectives.\nCathelicidin-derived peptides may be used prophylactically as immunomodulators and adjuvants in veterinary medicine.\nHost-directed therapy may include innate immune training by epigenetic reprogramming. The presentations will be followed by a Q&A session.\n\nSpeakers: R.E.W. (Bob) Hancock\, University of British Columbia (Canada); Henk P. Haagsman\, Utrecht University (Netherlands) \nModerator: Neeloffer Mookherjee\, Departments of Internal Medicine and Immunology\, University of Manitoba (Canada) \nClick here to learn more and register.
URL:https://carb-x.org/event/live-webinar-gardp-revive-manipulating-the-host-response-to-treat-infections/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210118
DTEND;VALUE=DATE:20210121
DTSTAMP:20260403T194301
CREATED:20201202T234358Z
LAST-MODIFIED:20201202T234358Z
UID:4671-1610928000-1611187199@carb-x.org
SUMMARY:Keystone Symposia: Harnessing the Microbiome for Disease Prevention and Therapy
DESCRIPTION:Joint meeting with: The Microbiome: From Mother to Child\nJanuary 18-20\, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET* \nOur understanding of the microbiome is advancing rapidly\, and continues to productively move through the discovery phase\, with numerous correlations being established between specific commensal microbes or microbiota compositions and a wide range of diseases that includes infections\, inflammatory conditions\, metabolic disease\, autoimmunity and neurologic syndromes. The initial discovery of these potentially important correlations has led many laboratories around the world to probe the molecular mechanisms that form the causal link between specific commensal microbes and disease development\, progression and resolution. Although there have been great advances\, culturing many of the prevalent and metabolically active obligate anaerobic commensals remains a challenge. Exciting advances\, however\, are emerging from laboratories developing tools to genetically manipulate key commensal organisms\, facilitating experimental studies that are identifying the small\, bioactive molecules they produce\, some of which have therapeutic potential. Studies of the impact of bacteriophage on the microbiota also suggest that they may have therapeutic potential. This Keystone conference will focus on recent advances that demonstrate\, at the cellular and molecular level\, the impact of the microbiota and its products on disease susceptibility/resistance\, with an emphasis on microbial and host metabolism\, inter-microbial interactions and the amelioration of diseases. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/keystone-symposia-harnessing-the-microbiome-for-disease-prevention-and-therapy/
LOCATION:VIRTUAL EVENT
END:VEVENT
END:VCALENDAR